GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Armata Pharmaceuticals Inc (AMEX:ARMP) » Definitions » FCF Yield %

Armata Pharmaceuticals (Armata Pharmaceuticals) FCF Yield % : -49.72 (As of May. 11, 2024)


View and export this data going back to 1994. Start your Free Trial

What is Armata Pharmaceuticals FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Armata Pharmaceuticals's Trailing 12-Month Free Cash Flow is $-55.57 Mil, and Market Cap is $111.76 Mil. Therefore, Armata Pharmaceuticals's FCF Yield % for today is -49.72%.

The historical rank and industry rank for Armata Pharmaceuticals's FCF Yield % or its related term are showing as below:

ARMP' s FCF Yield % Range Over the Past 10 Years
Min: -908.73   Med: -55.24   Max: -1.93
Current: -49.72


During the past 13 years, the highest FCF Yield % of Armata Pharmaceuticals was -1.93%. The lowest was -908.73%. And the median was -55.24%.

ARMP's FCF Yield % is ranked worse than
74.74% of 1556 companies
in the Biotechnology industry
Industry Median: -14.17 vs ARMP: -49.72

Armata Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.


Armata Pharmaceuticals FCF Yield % Historical Data

The historical data trend for Armata Pharmaceuticals's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Armata Pharmaceuticals FCF Yield % Chart

Armata Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -49.01 -34.23 -16.75 -77.40 -47.48

Armata Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -89.51 -129.75 -119.29 -48.72 -35.91

Competitive Comparison of Armata Pharmaceuticals's FCF Yield %

For the Biotechnology subindustry, Armata Pharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Armata Pharmaceuticals's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Armata Pharmaceuticals's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Armata Pharmaceuticals's FCF Yield % falls into.



Armata Pharmaceuticals FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Armata Pharmaceuticals's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-55.567 / 117.038196
=-47.48%

Armata Pharmaceuticals's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-10.506 * 4 / 117.038196
=-35.91%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Armata Pharmaceuticals FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Armata Pharmaceuticals FCF Yield % Related Terms

Thank you for viewing the detailed overview of Armata Pharmaceuticals's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Armata Pharmaceuticals (Armata Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
4503 Glencoe Avenue, Marina del Rey, CA, USA, 90292
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Further, the company is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.
Executives
Richard Rychlik officer: Corporate Controller and PFO 5005 MCCONNELL AVENUE, LOS ANGELES CA 90066
Deborah Birx director, officer: Chief Executive Officer 3300 LOWELL STREET NW, WASHINGTON DC 20008
Julianne Averill officer: Chief Financial Officer 361 NEWBURY STREET, SUITE 500, BOSTON MA 02115
Erin Butler officer: Vice President,Finance & Admin 4375 LOMA RIVIERA COURT, SAN DIEGO CA 92110
Theravance Inc director, 10 percent owner 1350 OLD BAYSHORE HIGHWAY, SUITE 400, BURLINGAME CA 94010
Jules Haimovitz director 601 108TH AVENUE NE, SUITE 1200, BELLEVUE WA 98004
Innoviva Strategic Opportunities Llc director, 10 percent owner 1209 ORANGE STREET, WILMINGTON DE 19801
Robin Kramer director 999 VANDERBILT BEACH ROAD, 3RD FLOOR, NAPLES FL 34109
Steven Robert Martin officer: Chief Financial Officer 11011 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Kostas D Odysseas director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarah J. Schlesinger director C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jeremy Curnock Cook director TARGETED GENETICS CORP, 1100 OLIVE WAY STE 100, SEATTLE WA 98101
Michael S Perry director C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
Todd C. Peterson director C/O ARMATA PHARMACEUTICALS, INC., 4503 GLENCOE AVENUE, MARINA DEL REY CA 90292
H Stewart Parker director

Armata Pharmaceuticals (Armata Pharmaceuticals) Headlines

From GuruFocus